Illumina, Inc. (ILMN)

NASDAQ • Healthcare

$273.68

+$1.68 (+0.6%)

Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$272.71

Day Range$270.58 - $280.17

Avg. Volume (3M)3.9M

Market Cap$41.4B

P/E Ratio50.6

52 Week Range

$88$280.17

Next EarningsIn 29 daysOct 29, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$1.1B100%

Gross Profitminus cost of goods$770M66%

Operating Incomeminus R&D and overhead$245M21%

Net Incomeminus taxes and the rest$207M18%

In plain terms: out of every $100 in revenue, Illumina, Inc. keeps $18 as net profit.

Fundamentals & Financials

Revenue (TTM)

$4.4B

Net Income (TTM)

$825M

EPS (TTM)

$5.41

ROA (TTM)

12.41%

Current Ratio

1.8

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+16.7%Q3 2025$1.19

+14.5%Q4 2025$1.34

+8.9%Q1 2026$1.35

+9.5%Q2 2026$1.15

+6.5%Q3 2026$1.31

Oct 29

in 29 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +6.5%

Illumina beat expectations on both the top and bottom line in the second fiscal quarter of 2026, reported July 30, 2026, with adjusted EPS of $1.31 topping the $1.23 estimate (+6.5%) and revenue of $1.159 billion topping the $1.131 billion estimate (+2.5%). Revenue rose 9.6% to about $1.2 billion (up from $1.057 billion a year ago), while gross margin was 66.4% and operating margin was 21.1%. On profitability, GAAP gross profit came in at roughly $770.0 million and operating income was about $245.0 million, alongside GAAP net income of about $207.0 million, down 11.9% from roughly $235.0 million a year ago. The company generated operating cash flow of about $201.0 million during the quarter. For the next period, consensus calls for EPS of $1.38 on revenue of $1.153 billion.

Next report — what to expect

Illumina, Inc. (ILMN) is scheduled to report earnings on October 29, 2026. Wall Street is looking for consensus EPS of $1.36 on consensus revenue of $1.15 billion. For trailing context, revenue rose +9.6% year over year last quarter. Illumina has beaten EPS in 7 of 8 most recent quarters.

View full earnings history

About Illumina, Inc.

Illumina, Inc. (NASDAQ: ILMN) develops genetic and genomic analysis tools for the healthcare sector, selling instruments, consumables, services, and cancer detection tests used across research and clinical settings in medical diagnostics and research. In FY2025, the company recorded $4.3 billion in revenue.

Name

Illumina, Inc.

CEO

Jacob Thaysen

Website

www.illumina.com

Industry

Healthcare

Year Founded

1998

Employees

8,600

Today's Snapshot

AI-generated

ILMN closed 0.6% higher at 273.68, outperforming a weaker sector. Trading was lighter than usual, with volume about half of its usual level. Illumina presented TruPath Genome, a genomic testing product, in a new evaluation.

Trading Volume

Below 10d avg (6.1M)

2.8M

vs S&P 500 Today

Moderate Outperformance

+0.43%

Updated: September 30, 2026 at 20:08 UTC

Technical Indicators

6 Buy0 Neutral2 Sell

ILMN is a Strong Buy driven by a robust trend and strong momentum as price sits substantially above all key moving averages and ADX signals a powerful trend. MACD and momentum readings are bullish and the stock remains well above the pivot level, yet several overbought measures — RSI, Stochastic and MFI — are extreme and caution that upside may be stretched. Additionally, OBV shows a divergence with selling pressure that contrasts with price strength. Technical takeaway: Strong Buy — trend and momentum are strong, but overbought readings and volume divergence warrant caution.

All signals